FDA Warning Wire: Zimmer Rapped In Inspection, Again

Law360, New York (January 24, 2017, 8:35 PM EST) -- The U.S. Food and Drug Administration again found issues with one of medical device maker Zimmer Biomet’s plants, took a British drug maker to task over the presence of metal particles in a leukemia drug and criticized fishy safety protocols at an Icelandic fishery.

Here’s this week’s roundup of the agency’s enforcement actions

Zimmer Biomet Faulted For Plant Conditions, Again

The FDA issued one of its so-called Form 483 reports detailing, in nearly 60 heavily redacted pages, its findings from an inspection of Zimmer Biomet’s Warsaw, Indiana, plant from September to November.

All in all, the report laid out 14 observations...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!